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Prolonged in vivo tumour retention of a human diabody
targeting the extracellular domain of human HER2Ineu
GP Adams1, R Schier2, AM McCall1, RS Crawford2, EJ Wolf', LM Weiner' and JD Marks2
'Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA; 2Department of Anesthesiology and Pharmaceutical Chemistry,
University of California, San Francisco, CA 94110, USA
Summary Single-chain Fv (scFv) molecules exhibit highly specific tumour-targeting properties in tumour-bearing mice. However, because of
their smaller size and monovalent binding, the quantities of radiolabelled scFv retained in tumours limit their therapeutic applications.
Diabodies are dimeric antibody-based molecules composed of two non-covalently associated scFv that bind to antigen in a divalent manner.
In vitro, diabodies produced from the anti-HER2/neu (c-erbB-2) scFv C6.5 displayed approximately 40-fold greater affinity for HER2Ineu by
surface plasmon resonance biosensor measurements and significantly prolonged association with antigen on the surface of SK-OV-3 cells
(tl,2 cell surface retention of > 5 h vs 5 min) compared with C6.5 scFv. In SK-OV-3 tumour-bearing scid mice, radioiodinated C6.5 diabody
displayed a highly favourable balance of quantitative tumour retention and specificity. By as early as 4 h after i.v. administration, significantly
more diabody was retained in tumour (10 %ID g-1) than in blood (6.7 %ID ml-') or normal tissue (liver, 2.8 %ID g-'; lung, 7.1 %ID g-1; kidney,
5.2 %ID g-1). Over the next 20 h, the quantity present in blood and most tissues dropped approximately tenfold, while the tumour retained
6.5 %ID g-1 or about two-thirds of its 4-h value. In contrast, the 24-h tumour retention of radioiodinated C6.5 scFv monomer was only
1 %ID g-1. When diabody retentions were examined over the course of a 72-h study and cumulative area under the curve (AUC) values were
determined, the resulting tumor-organ AUC ratios were found to be superior to those previously reported for other monovalent or divalent
scFv molecules. In conclusion, the diabody format provides the C6.5 molecule with a distinct in vitro and in vivo targeting advantage and has
promise as a delivery vehicle for therapeutic agents.
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A major goal of antibody-based cancer therapy has been to specifi-
cally deliver toxic payloads, such as radioisotopes, toxins or drugs,
to tumours. The range of antibody binding site-based molecules
includes IgM (1000 kDa), IgG (150 kDa), F(ab')2 (100 kDa), Fab
(50 kDa), (scFv')2 (55 kDa) and scFv (25 kDa). In immunodefi-
cient mice, larger molecules such as IgG and F(ab')2 fragments are
retained at high levels in human tumour xenografts with a low
degree of specificity (Milenic et al, 1991; Adams et al, 1992), while
smaller molecules such as scFv, (scFv')2 and Fab are retained in
tumour at comparatively lower levels with greatly improved speci-
ficity (Beaumier et al, 1985; Colcher et al, 1990; Milenic et al,
1991; Adams et al, 1993). The most prominent determinant of the
above targeting properties is the size of the antibody-based mole-
cule relative to the renal threshold for first-pass clearance. Another
important feature of antibody-based molecules is valence, as signif-
icantly greater tumour retention has been associated with multiva-
lent binding to target antigen (Milenic et al, 1991; Adams et al,
1993, 1996; Wolf et al, 1993). Recently, attention has focused upon
the generation of divalent scFv-based molecules with molecular
weights in the range of the renal threshold for first-pass clearance.
These include 50-kDa diabodies (Holliger, 1993), 55-kDa (scFv')2
(Adams et al, 1993), 60 to 65-kDa amphipathic helix-based scFv
dimers (Pack et al, 1992, 1993) and 80-kDa (scFv-CH3)2 LD mini-
bodies and Flex minibodies (Hu Shi-zhen et al, 1996). While each
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of these proteins is capable of binding two antigen molecules, they
differ in the orientation, flexibility and span of their binding sites.
In this report, we examine the potential of diabody molecules to
function as vehicles for the specific, quantitative delivery of
radioisotopes to tumours. Diabodies are scFv dimers in which each
chain consists of a variable heavy (VH) domain connected to a
variable light (VL) domain using a peptide linker that is too short
to permit pairing between domains on the same chain (Holliger et
al, 1993). Consequently, pairing occurs between complementary
domains of two different chains, creating a stable non-covalently
bound dimer with two binding sites (Figure 1) (Perisic et al, 1994).
We have used the human anti HER2/neu (c-erbB-2) scFv C6.5
(Schier et al, 1995) to construct a C6.5 diabody. While HER2/neu
expression on normal human tissues is limited, it is overexpressed
in a number of cancers, including breast and ovarian carcinoma
(King et al, 1985; Kraus et al, 1987; van de Vijver et al, 1987;
Berchuck et al, 1990), gastric tumours and colon adenocarcinomas
(Yokota et al, 1988). Its relevance as a target for antibody-based
therapy is further underscored by the correlation of HER2/neu
overexpression with a poor prognosis in several malignancies
(Slamon et al, 1987; Allred et al, 1992). Here, we present the C6.5
diabody's in vitro binding characteristics and in vivo distribution
in tumour-bearing scid mice.
METHOD
C6.5 scFv and diabody production
The C6.5 scFv in pUC119mycHis was expressed from E. coli
TG1 and purified by immobilized metal chelate chromatography
1405
1406 GP Adams et al
;: .,. F. - ..
... FY
I,.Fx . h sFv
*gO sFv produced w-it sho-t lkitm Diabody
Figure 1 The structures of an IgG molecule (-150 kDa), an Fv fragment (-22 kDa), a recombinant scFv (-25 kDa) molecule, a dimeric (scFv')2 molecule
(-55 kDa) and a diabody molecule (-50 kDa) are presented. While they are identical, the two diabody components are illustrated with different shading to clarify
the structure
(IMAC) followed by fast protein liquid chromatography (FPLC)
size-exclusion chromatography using a Superdex 75 column as
previously described (Schier et al, 1995). To create the C6.5
diabody, the C6.5 VH and V. genes were joined together by poly-
merase chain reaction (PCR) splicing by overlap extension using
an oligonucleotide that encoded a five amino acid linker (G4S)
between the C-terminus of the VH and the N-terminus of the VA
gene. First, the C6.5 VH and V. genes were amplified using PCR
from C6.5 scFv DNA using the primers LMB3 and DIAFOR (5'-
CCA CCT GAG GAG ACG GTG ACC-3') (Marks et al, 1991) for
the VH gene and LMB2 and DIABACK (5'-GGT CAC CGT CTC
CTC AGG TGG AGG CGG TTC ACA GTC TGT GTT GAC
GCA GCC G-3') (Marks et al, 1991) for the V. gene. The VH and
V. genes were gel purified and 200 ng of each combined in a 50-,ul
reaction with 5 U of Vent DNA polymerase (New England
Biolabs). The reaction mixture was cycled seven times to join the
fragments (94°C for 1 min, 50°C for 1 min, 72°C for 1.5 min) after
which 20 pM of the primers LMB2 and LMB3 were added, and the
reaction cycled 25 times to amplify the products. The resulting
diabody gene product was digested with NcoI and NotI, gel puri-
fied and ligated into NcoIINotI-digested pUC 1l9mycHis (Schier
et al, 1995). The ligation mixture was used to transform E. coli
TG1, and clones containing the correct insert identified by PCR
screening and DNA sequencing. Native diabody was expressed
(Breitling, 1991) and purified from the bacterial periplasm using
IMAC (Hochuli et al, 1988) followed by FPLC size-exclusion
chromatography using a Superdex 75 column.
Measurement of C6.5 scFv and diabody affinity for
c-erbB-2
The affinities of C6.5 scFv and C6.5 diabody for the HER2/neu
ECD were determined using surface plasmon resonance in a
BlAcore (Pharmacia, Sweden) generally as previously described
(Schier et al, 1995, 1996). In a BlAcore flow cell, approximately
1400 RU (for the scFv) or 600 RU (for the diabody) of HER2/neu
ECD (90 kDa; McCartney, 1994) were coupled to a CM5 sensor
chip (J0nsson et al, 1991). Association rates were measured under
continuous flow of 5 pl min-1 using concentrations ranging from
5.0 x 10-8 to 8.0 x 10-7 M. k1on was determined from a plot of [In
(dR/dt)]/t vs concentration (Karlson et al, 1991). Dissociation rates
were measured using a constant flow of 25 pl min-' and an scFv or
diabody concentration of 1.0 x 10- M. Density of HER2/neu ECD
on the sensor chip surface was calculated to be 4.2 x 103 molecules
pm 2, assuming 600 RU = 0.007 pmol HER2/neu mm-2
Cell-surface retention assay
In order to assess the impact of the divalent nature of the C6.5
diabody on its association with cell-bound HER2/neu, an in vitro
cell-surface retention assay was performed. For this assay, the
C6.5 scFv and diabody were biotinylated using an ImmunoPure
NHS-LC-Biotinylation kit (no. 21430, Pierce, Rockford, IL,
USA). Twelve micrograms of biotinylated C6.5 scFv or diabody
were incubated with 1.2 x 107 HER2/neu-overexpressing SK-OV-
3 (HBT 77; American Type Culture Collection, Rockville, MD,
USA) cells (Weiner et al, 1993) in a total volume of 0.5 ml of
FACS buffer (0.154 M sodium chloride, 10 mm sodium phosphate,
1% bovine serum albumin, 0.1% sodium azide, pH 7.2) for 30 min
at room temperature. The cells were centrifuged at 500 g for 5 min
at 4°C, washed with 10 ml of ice-cold FACS buffer two times and
then resuspended gently in 12 ml ofFACS buffer at 37°C. The cell
suspensions were then incubated at 37°C with gentle shaking in a
water bath. To decrease the rebinding of dissociated biotinylated
diabody or scFv to the cells, at 15, 30, 45, 60, 90 and 120 min after
commencing the incubation the suspensions were pelleted at
500 g, the supematants were aspirated and the cells were gently
resuspended in fresh FACS buffer (37°C). Immediately after each
round of pelleting and resuspension, 0.5-ml aliquots containing
5 x 105 cells were removed in triplicate (i.e. at 0, 15, 30, 45, 60, 90
and 120 min), placed on ice for 5 min and centrifuged at 500 g for
5 min at 4°C. After removing the supernatants from the aliquots,
the cells were gently resuspended in 50 p1 of ice-cold FACS buffer
containing 50 pl of a 1:800 dilution of streptavidin-PE, incubated
on ice for 30 min and washed twice with FACS buffer at 4°C. The
cells were fixed with 1% paraformaldehyde and the degree of
fluorescence was determined by analysis on a FACscan flow
cytometer (Becton Dickinson, San Jose, CA, USA) as described
(Weiner et al, 1993). koff was calculated assuming first-order
kinetic using the formula F, = (F) x (e-kt), where F, = fluorescence
at time t, F = fluorescence at time 0 and k = k,ff. t112 was calculated
from koff using F/F, = 0.5. Density of HER2/neu on the surface of
SK-OV-3 cells was calculated to be 3.2-4.8 x 103 molecules jim-2,
assuming a cell diameter of 10 ,um and 1.0 x 106 HER2/neu ECD
per cell (observations ranged from 1.0 x 106 to 1.5 x 106 in
Scatchard assays; unpublished data).
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immunoreactivity of the radiopharmaceuticals was evaluated by
SDS-PAGE, high-performance liquid chromatography (HPLC) on
nt ei )a Superdex 75 column (Pharmacia) and in a live-cell binding assay
as described (Adams et al, 1993). The immunoreactivities of the
radiolabelled diabody and scFv monomer were found to be 87.6%
scFv and 65.3% respectively. The differences in immunoreactivity most
likely reflect the prolonged association of the diabody with its
antigen on the cell surface. Six- to eight-week-old CB. 17 Icr scid
mice were obtained from the Fox Chase Cancer Center Laboratory
Animal Facility. Then, 2.5 x 10'1 human ovarian carcinoma SK-OV-
3 cells were implanted s.c. on the abdomen of each mouse. When
the tumours had achieved a size of 50-200 mg (approximately 8
weeks), Lugol's solution was placed in their drinking water to block
thyroid accumulation of radioiodine, and biodistribution studies
were initiated. Twenty micrograns (100 ,ul) of radioiodinated
(.4~j~J~j3J diabody or scFv were administered by i.v. tail vein injection to each
Diabody mouse. Cohorts of five mice that had received the '251-C6.5 diabody
were sacrificed at 1, 4, 24, 48 and 72 h after injection and a single
cohort of five mice that had received the '25I-C6.5 scFv monomer
was sacrificed at 24 h after injection. The mean and s.e.m. of reten-
tion of each radiopharmaceutical in tissue (%ID g-') and blood
(%ID ml-') was determined as described (Adams et al, 1993).
Calculations of the estimated cumulative localization (AUC) of
10 15 20 25 30 35 40 diabody in tissues and blood were determined using the NCOMP
program (Laub, 1996). t,,2a and t,,2IB were calculated using the
lime (min) Rstrip program (Micromath, Salt Lake City, UT, USA).
.C profiles of the C6.5 diabody and C6.5 scFv. After IMAC Significance levels were determined using a Student's t-test on the
a Ni++ agarose column, the C6.5 diabody and scFv were Statworks program (Cricket Software, Philadelphia, PA, USA).
RESULTS
Diabody expression and characterization
The C6.5 diabody and scFv were secreted from E. coli grown in
shake flasks with typical yields of native protein after IMAC and
HPLC purification of approximately 1.0 mg 1- for the diabody and
5 mg 1-1 for the scFv. The C6.5 scFv eluted from a Superdex 200
column as a single peak of approximately 25 kDa, with minimal
analysed on a Superdex 200 column (Pharmacia). The C6.5 scFv eluted from
the Superdex 200 column as a single peak of approximately 25 kDa with
minimal evidence of aggregation, while the diabody eluted as a single peak of
approximately 50 kDa with no evidence of unassociated monomer
Biodistribution studies
C6.5 diabody and scFv were radiolabelled with iodine-125 using
the chloramine T (CT) method (I251IscFv = 1:6; CT/scFv = 1:10) as
previously described (Adams et al, 1992, 1993). The quality and
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Figure 3 In vitro characterization of the C6.5 diabody. C6.5 diabody and monomeric scFv were evaluated by surface plasmon resonance (BlAcore) as
described in Methods. The association and dissociation kinetics are displayed for the diabody (0) and scFv monomer (0) forms of C6.5 (A). In vitro cell-surface
retention profiles of biotinylated forms of the C6.5 diabody (0) and C6.5 monomer (0) were determined using SK-OV-3 cells, as described in the text, and the
results are displayed; s.e.m.s are less than 2% of the value presented (B)
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Figure 4 The in vivo tumour targeting of radioiodinated C6.5 diabody was
determined in a biodistribution study performed in SK-OV-3 tumour-bearing
scid mice. The plotted values represent the mean tumour (0) and blood (0)
retentions obtained from six mice per data point. The standard errors are
indicated
evidence of dimerization or aggregation (Figure 2A). The C6.5
diabody eluted from a Superdex 200 column as a single peak of
approximately 50 kDa, with no evidence of unassociated
monomer (Figure 2B). Both migrated under reducing conditions
on 12% SDS-PAGE gels as single bands of approximately 27 kDa
(data not shown).
The Kd of the C6.5 diabody for HER2/neu ECD was determined
by surface plasmon resonance in a BlAcore instrument to be 4.0 x
1l0 M (kon = 6.7 x 105 M-l s-i; koff = 2.7 x 104 s-i) 40-fold lower than
the Kd of the C6.5 scFv (1.6 x 10-8 M; kon = 4.0 x 105M-l s-i; koff =
6.3 x 10-3 s-i) (Figure 3A). The decrease in Kd was largely due to
reduction in koff, which correlated with a retention t12 of 43 min,
compared with 1.8 min for the scFv. In the BlAcore, the HER2/neu
ECD is chemically coupled to a three dimensional matrix of
carboxymethyl dextran, which bears little resemblance to the organi-
zation of HER2/neu on the cell surface. Therefore, the biological
relevance of the increased affinity of the diabody was determined in
an in vitro cell surface retention assay using biotinylated C6.5
diabody or scFv and human SK-OV-3 ovarian carcinoma cells over-
expressing HER2/neu. In this assay, the quantity of biotinylated
diabody or scFv retained on the surface of the SK-OV-3 cells over
time was determined by flow cytometry. Significantly longer reten-
tion of the C6.5 diabody was observed compared with the C6.5 scFv
(t12 scFv = 2.5 min vs t12 diabody = 5 h; P < 0.001) (Figure 2B). The
results compare favourably to t12 values calculated from the koff
measured in the BlAcore of 1.8 min for the scFv and 43 min for the
diabody. Thus the increase in apparent affinity was much greater on
the cell surface than on the carboxymethyldextran surface of the
BlAcore, despite the similarities in calculated density of HER2/neu
sites (3.2-4.8 x 103 sites jtm-2 on the cell surface vs 4.2 x 103 sites
gm-2 on the sensor chip surface).
Biodistribution assays
The in vivo targeting potential of the C6.5 diabody was assessed in
scid mice bearing s.c. SK-OV-3 tumours overexpressing the
HER2/neu antigen. The tumour, blood and organ retention of
radioiodinated C6.5 diabody was determined at 1, 4, 24, 48 and
72 h after its i.v. administration. After the injections, the diabody
displayed a rapid equilibration phase (t,,2a = 0.67 h) and subse-
quent slower elimination phase (tl,2 , = 6.42 h) from circulation, in
a pattern characteristic of small scFv-based molecules (Figure 4).
In contrast to the blood retention properties of the diabody, the
quantity retained in tumour rose from 6.9% ID g-' at 1 hour post
Table 1 Evaluation of [1251]C6.5 diabody in tumour-bearing scid mice
C6.5 diabody C6.5 scFv
Cumulative Tumour-organ
1 h 4 h 24 h 48 h 72 h AUC AUC ratio 24 h
Tumoura 6.9 10.1 6.5 2.4 1.4 405 - 1.0
Bloodb 21.5 (0.3) 6.7 (1.5) 0.7 (9.5) 0.1 (22.5) < 0.1 (24.0) 133 3.0 0.1 (19.1)
Liver 5.7 (1.2) 2.8 (3.6) 0.3 (21.0) 0.1 (22.5) 0.1 (15.0) 137 3.0 < 0.1 (25.4)
Kidneys 16.9 (0.4) 5.2 (1.9) 1.1 (6.0) 0.4 (6.7) 0.3 (4.5) 153 2.6 0.2 (6.3)
Lung 17.0 (0.4) 7.1 (1.4) 0.7 (8.8) 0.1 (19.7) 0.1 (18.2) 57 7.1 0.1 (17.0)
Spleen 4.3 (1.6) 3.5 (3.2) 0.4 (16.1) 0.1 (20.6) 0.1 (17.0) 61 6.6 <0.1 (24.5)
Heart 13.1 (0.5) 4.7 (2.2) 0.4 (17.5) 0.1 (31.0) <0.1 (31.7) 93 4.4 <0.1 (37.2)
Stomach 4.5 (1.6) 7.9 (1.4) 1.4 (5.7) 0.3 (11.6) 0.3 (6.6) 129 3.1 0.2c (6.2)
Intestine 1.6 (4.5) 2.5 (4.6) 0.3 (22.3) 0.1 (33.4) 0.1 (24.7) 37 10.9 < 0.1 (25.8)
Bone 2.3 (3.3) 1.9 (6.0) 0.1 (40.6) < 0.1 (84.3) < 0.1 (65.0) 31 13.1 < 0.1c (34.2)
Muscle 1.2 (5.8) 1.5 (7.1) 0.2 (34.3) <0.1 (44.6) <0.1 (53.4) 37 10.9 < 0.1 (49.8)
aExpressed as %ID g-1 tissue. bExpressed as %ID ml-1 blood. cs.e.m. <45%. C.B 17/ICR-scid mice bearing 50- to 200-mg s.c. SK-OV-3 tumours were used in
these studies. Cohorts of five mice per time point were given 20 9g of [1251]C6.5 diabody by i.v. injection. The mice were sacrificed at the indicated times and the
tumour, blood and normal tissue retention was determined and expressed as a percentage of the injected dose localized per g of tissue (%ID g-1) or per ml of
blood (%ID ml-') as described in Methods. Tumour-organ ratios are presented in parentheses. For each value presented, the s.e.m. was less than 30%, unless
otherwise indicated. The cumulative diabody retention (AUC) in each tissue was determined as described and is expressed in arbitrary units to facilitate the
determination of the tumour to organ AUC ratios.
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injection to a peak of 10.1 %ID g-' at 4 h post injection and slowly
decreased to 6.5% ID g-' and 1.4% ID g-' at 24 and 72 h respec-
tively (Table 1 and Figure 4). The retention of the diabody in
normal organs reflected the concentration present in blood over the
course of the study with the notable exception of the kidneys,
which function as the major elimination route for scFv-based
reagents (Table 1). The cumulative residence of the radioiodinated
diabody in tumour and normal organs, expressed as AUCs, was
determined to predict the therapeutic potential for this molecule.
Over the course of the study, favourable tumour to organ AUC
ratios were observed for a number of organs, including liver (3.0),
spleen (6.6), bone (13.1), kidneys (2.6) and blood (3:1) (Table 1).
While the activity in the bone marrow compartment is difficult to
measure directly, it is routinely estimated based upon the observa-
tion that one-fourth of the bone marrow compartment is composed
of blood (Siegel et al, 1990). As HER2/neu is not expressed on
cells in the marrow, the diabody will not specifically bind to
marrow, just as it does not bind to other tissues lacking HER2/neu
(e.g. liver, spleen and muscle). Therefore, the radioiodinated
diabody present in the bone marrow compartment can be solely
attributed to that present in the blood portion of the bone marrow.
Accordingly, the tumour to bone marrow ratio was estimated as
12:1 (25% of the tumour-blood ratio).
The biodistribution of the [1251]C6.5 scFv monomer was
performed at 24 h after administration for comparative purposes
and was found to be virtually identical to that previously reported
for this and other scFv monomers of similar affinity, with 1.0 % ID
g-' retained in tumour, 0.04 % ID g-I in liver and 0.05 % ID ml-' in
blood (Table 1) (Colcher et al, 1990; Milenic et al, 1991; Adams et
al, 1993; Schier et al, 1995). This clearly demonstrated the signifi-
cantly increased tumour retention (P = 0.00043) conferred by the
diabody format. The prolonged blood retention of the larger
diabody molecule may also account for some of the increased
tumour retention. This is evidenced by the 24-h tumour-blood
ratios of about 9:1 for the diabody and 20:1 for the monomer.
DISCUSSION
Here we describe the production and in vitro and in vivo properties
of the C6.5 diabody molecule specific for HER2/neu. The C6.5
diabody was expressed and purified in high yield from E. coli as
native protein without refolding. Compared with the scFv from
which it was derived, the diabody exhibited a significantly lower Kd
and slower kff from HER2/neu that was either immobilized on a
BlAcore sensor chip or as expressed on the surface of tumour cells.
In vivo, radioiodinated C6.5 diabody displayed an excellent balance
of quantitative tumour deposition and specificity. Peak tumour
values of 10 %ID g' were observed at 4 h after intravenous
administration and persisted through 24 h (6.5 %ID g-') and 72 h
(1.2 %ID g-') post injection. In contrast, the diabody was rapidly
cleared from the circulation and antigen-negative organs, as its
molecular weight (50 kDa) is less than the renal threshold. As a
result, significantly more diabody was retained in tumour than in
any other organ at all but the earliest time points studied. This
yielded tumour-normal organ AUCs of 3:0 (tumor-blood) to 13.1:1
(tumour-bone). Furthermore, as we and others have previously
demonstrated, antibody-based molecules with sizes beneath the
renal threshold for first-pass clearance are typically eliminated in a
biphasic manner, with a rapid initial equilibration phase and a
slower elimination phase (reviewed in Huston et al, 1996). This
suggests that the sampling times used in this study may have
exaggerated the blood AUC value for the interval between 4 and
24 h. Thus, it is likely that the inclusion of additional sampling
times (i.e. 6, 12 and 16 h post injection) would reveal lower blood
retentions and hence, more specific tumour localization. As the
C6.5 diabody was developed from a phage display-derived scFv, a
C6.5 IgG molecule was not available for a direct comparison
between these two divalent structures. However, a reasonable
comparison can be made using an IgG molecule specific for a
different epitope on the HER2/neu antigen. We have previously
reported on the distribution of 741F8 IgG, which, like many other
monoclonal antibodies targeting cell-surface tumour-associated
antigens, exhibits a high degree of tumour uptake (e.g. 20 %ID g-')
with very poor targeting specificity (tumour-blood ratios < 1:1)
(Weiner et al, 1995). Therefore, even though the degree of tumour
retention observed with the C6.5 diabody was less than that
observed with anti-HER2/neu IgG, the increased targeting speci-
ficity associated with the diabody format results in an advantage.
Compared with the scFv, the increased tumour deposition of the
diabody could result from its increased size or increase in apparent
affinity (avidity). The increased size of the C6.5 diabody led to a
slower redistribution and elimination t12 than was observed for the
C6.5 scFv. This leads to higher blood levels and prolongation of
the concentration gradient for diffusion from blood into tumour.
However, Fab are of similar size and have similar pharmaco-
kinetics, but do not provide as great an increment in quantitative
tumour retention compared with scFv (Milenic et al, 1991; Adams
et al, 1993). Thus, size alone is unlikely to account for the
increased tumour deposition and retention of the diabody, which
instead must be at least partly due to an increase in apparent
affinity resulting from avidity. A priori, it was unclear to what
extent an increase in apparent affinity would occur with the
divalent diabody molecule. The Fab arms of the IgG molecule are
extremely flexible, because of the hinge (Ferencik, 1993). In
contrast, the two binding heads of the diabody are oriented 1800
apart in a rigid configuration (Perisic et al, 1994). Thus, the extent
to which the diabody could engage two antigens simultaneously,
particularly on the cell surface, was unclear. As determined using
surface plasmon resonance in a BlAcore, the apparent affinity of
the diabody is 40-fold higher than the scFv, largely because of a
40-fold reduction in koff. The dissociation of diabody from the cell
surface was sevenfold slower than observed on the BlAcore, with
a koff approximately 280-fold slower than the scFv. As the calcu-
lated antigen density on the BIAcore sensor chip surface and the
cell surface are approximately the same, these differences may
result from the greater mobility of HER2/neu ECD in the cell
membrane, leading to bivalent binding without steric strain.
Monoclonal antibody (MAb)-based radioimmunotherapy (RAIT)
has shown notable promise in the treatment of haematological
malignancies (Kaminski et al, 1993; Press et al, 1993), but progress
in the therapy of solid tumours has been hindered by a number of
factors dictated by tumour physiology (Jain, 1990). First, the disor-
dered vasculature of solid tumours leads to a heterogeneous intratu-
moral distribution of MAb. Second, the paucity of draining
lymphatics in tumours results in elevated hydrostatic pressure,
limiting the diffusion of large molecules such as IgG to 100 ,um in
1 h, 1 mm in about 2 days and 1 cm in about 7-8 months. To obtain
sufficient tumour localization for radiolabelled MAb to provide ther-
apeutic effects, the MAb must remain in circulation long enough to
diffuse from blood into tumour. At the same time, the radiolabelled
MAb must be eliminated from circulation rapidly enough to
diminish normal organ retention and prevent unacceptable toxicities.
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To achieve successful RAIT, a proper balance must be established
between these competing requirements. We hypothesized that an
appropriate balance could be accomplished by using small, high-
affinity, multivalent, antibody-based molecules. Decreasing the
size of the molecule increases both its diffusion rate into tumour
(Jain, 1990) and its rate of elimination from circulation, thus
enhancing both the degree of tumour penetration and the specificity
of tumour retention. While the optimal size for an antibody-based
construct has yet to be identified, we believe it will fall below the
renal threshold for first-pass clearance (about 65 kDa). When
administered by a continuous i.v. infusion, such molecules could be
maintained at steady-state levels in circulation, and controlled
gradients from blood into tumour could be established. This would
facilitate deep penetration into tumour and highly specific tumour
retention when the molecules are rapidly eliminated from circula-
tion upon the termination of the infusion. A variety of molecular
structures that span a wide range of sizes are available. These
include 80-kDa (scFv-CH3)2 minibodies (Hu Shizhen et al, 1996),
50-kDa diabodies (Holliger et al, 1993), 27-kDa scFv (Bird et al,
1988; Huston et al, 1988) and individual 12- to 13-kDa VH or VL
chains (Ward et al, 1989). While the smallest molecules will be
capable of the greatest diffusion into solid tumours, their adminis-
tration will require careful management to maintain the blood
concentrations required to permit diffusion through tumour.
Increasing the functional affinity may help 'trap' the scFv that
diffuses into tumour, localizing it long enough to facilitate thera-
peutic applications. This can be accomplished by manipulating the
intrinsic affinity properties (Schier et al, 1996) or through the
creation of multivalent binding proteins. While Weinstein has
hypothesized that the diffusion of high-affinity MAb into tumour is
hindered by binding to antigen-bearing cells close to blood vessels
(Fujimori et al, 1989; Juweid et al, 1992), this may be overcome by
enhancing the diffusion gradient from blood into tumour through
the administration of large doses. Finally, the potential of engi-
neered antibody-based proteins to target tumours in humans in a
highly specific manner was recently demonstrated using radio-
immunoimaging performed by Begent et al (1996). Given that
successful tumour localization in the above study was achieved
with a small, monovalant scFv, it is our belief that the larger,
divalant diabody molecule used here will also exhibit impressive
tumour targeting in patients.
Of the divalent scFv-based molecules produced to date, before
this study, reports of in vivo assays only exist for the (scFv')2 and
the minibody. Previously, we have shown that the tumour retention
of a 20-jig dose of the anti-HER2/neu 741F8 (scFv')2 in scid mice
bearing relevant tumours is twice that seen with 741F8 scFv
monomer (Adams et al, 1993). While the specificity of tumour
retention at 24 h post injection was very high, as evidenced by
tumour-blood and tumour-muscle ratios of 10:1 and 75:1, respec-
tively, the quantity of (scFv')2 retained in tumour (1.6 %ID g-1)
was insufficient to mediate therapeutic effects or predict for
therapeutic dosimetry in tumours. Hu Shi-Zhen et al (1996) have
recently reported excellent selective tumour retention after the
administration of small quantities (0.1-0.2 ,ug per mouse, or
0.005-0.01 ,ug/g-' body weight) of anti-CEA (scFv-CH3)2 mini-
bodies to tumour-bearing athymic mice, with average 24-h reten-
tions of 29 %ID g-' and 8 %ID g-' in tumour with flex and LD
minibodies respectively. While the mass of the C6.5 diabody
(50 kDa) lies just below the renal threshold for first-pass clear-
ance, the two minibody species have molecular weights of approx-
imately 80 kDa and are above the threshold. This is evidenced by
the faster clearance of the diabody from circulation (0.7 %ID ml
vs 2.1 %ID ml,-1 respectively, for the diabody and minibodies at
24 h post injection), which probably leads to a lower cumulative
blood, and hence marrow, exposure for the diabody. However, the
greater peak tumour retention of the minibody leads to similar
tumour-blood AUCs for both molecules. Clearly, the parallel eval-
uation of identical doses of a series of reagents (i.e. scFv, (scFv')2,
diabody and minibody) with identical specificity is desirable to
definitively address the role of size on the in vivo tumour-targeting
properties of these recombinant antibody-based molecules.
The cumulative retention (AUC) of C6.5 diabody in tumour and
normal tissues was calculated to predict the therapeutic potential
of diabodies as vehicles for RAIT. RAIT efficacy is dependent
upon the delivery of lethal doses of radiation to tumour without
exceeding the doses tolerated by the bone marrow (200-300 cGy)
and organs involved in the catabolism of the radiopharmaceutical,
such as the kidneys (1500 cGy) and the liver (4000 cGy) (Bentel et
al, 1989). In this study with the C6.5 diabody, we calculated
tumour to organ ratios ranging from 3:1 to 13:1. The tumour-bone
marrow estimate of 12:1 and tumour-kidney value of 2.6:1 would
permit the delivery of approximately 4000 cGy to tumour at a
marrow dose of 250 cGy. This represents a significant improve-
ment over results in preclinical models observed with other anti-
body-based molecules, including scFv (Adams et al, unpublished
results), (scFv')2 (Weiner et al, 1995), Fab (Yorke et al, 1991),
F(ab')2 (Stein et al, 1991, 1994) and IgG (Stein et al, 1991;
Molthoff et al, 1991, 1992). While the predicted tumour-blood
AUCs for Flex minibodies are similar to those reported here for
the C6.5 diabody, the smaller diabody structure may confer an
advantage when penetration of large solid tumours is required.
As the divalent binding of a diabody molecule to antigen on the
surface of a tumour cell molecule is dependent upon both the
density of the antigen and its orientation, it is likely that such
binding would only occur when the antigen density is high. While
the C6.5 diabody remains bound to the tumour cells in vitro
(Figure 3B) and is retained in tumour in vivo (Figure 4) signifi-
cantly longer than is its monomeric scFv form, it is likely that
diabody bound to normal tissue expressing low concentrations of
HER2/neu would bind in a monovalent manner and exhibit the
rapid dissociation kinetics characteristic of the C6.5 scFv. To
confirm this hypothesis, the in vitro and in vivo binding profiles of
C6.5 diabody and C6.5 scFv require evaluation in tumour cell
lines and tumours with a wide range of HER2/neu expression.
If the prolonged retention of the C6.5 diabody on the surface of
cells and in tumours overexpressing HER2/neu is mediated by
divalent binding, it may exert a direct biological impact on these
cells. Homodimerization of HER2/neu or heterodimerization of
HER2Ineu with c-erbB-3 or c-erbB-4 has recently been found to
be required for signal transduction after the binding of heregulin to
c-erbB-3 or c-erbB-4 (Earp et al, 1995; Wallasch et al, 1995). The
possibility that divalent binding of two HER2/neu molecules by
C6.5 diabody facilitates the homodimerization of HER2/neu with
subsequent signal transduction is intriguing. Alternatively, it is
possible that cytostatic effects could be triggered by the immobi-
lization of HER2/neu on the cell surface to prevent the homo-
dimerization of the molecule's transmembrane region. Either of
these mechanisms may be responsible for reports of synergistic
effects between some anti-HER2/neu monoclonal antibodies and
chemotherapeutic agents, such as taxol or cisplatin (Hancock et al,
1991). Accordingly, the potential of the C6.5 diabody to dimerize
HER2/neu, trigger signal transduction and inhibit tumour cell
British Journal of Cancer (1998) 77(9), 1405-1412 0 Cancer Research Campaign 1998
Anti-HER21neu diabodies 1411
growth in the presence of chemotherapeutic agents has been
studied. However, when the C6.5 diabody has been assayed for
growth inhibition potential by in vitro MTT [3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide] incorporation assays,
concentrations of up to 10 ig ml for 7 days do not significantly
inhibit the growth of SK-OV-3 cells overexpressing the HER2/neu
antigen (unpublished results). Accordingly, it is probable that the
C6.5 diabody by itself is not capable of exerting cytostatic effects.
Continued improvements in antibody engineering have led to
increasingly sophisticated structures that address impediments to
successful tumour targeting. The C6.5 diabody may be an effective
targeting vehicle for RAIT. In addition, this molecule may provide
a useful platform for the creation of affinity mutants with slower
koff rates or for the creation of fusion proteins containing other anti-
bodies, cytokines, chemotactic factors or toxins.
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